Summary
Blinatumomab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). ClinicalTrials.gov lists 8 registered trials linking Blinatumomab to Non-Hodgkin Lymphoma (NHL): 5 are currently recruiting; 2 are active or not yet recruiting; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT07476729). It plans or enrolled 750 participants. Registration activity spans 2017 to 2026. The literature layer holds 5 publications for this pair: 5 clinical trial publications. Publication years run from 2016 to 2026. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Non-Hodgkin Lymphoma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 57.0 (trials 27.0, literature 10.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 5 recruiting, 2 active / not yet recruiting, 0 completed, 1 other |
| Linked publications | 5 (5 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BCR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) 2026 | not yet recruiting | Phase 3 | 750 |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia 2017 | recruiting | Phase 3 | 303 |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia 2025 | recruiting | Phase 2 | 153 |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia 2022 | active, not recruiting | Phase 1 | 20 |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia 2026 | recruiting | Phase 1 | 26 |
| NCT03605589 | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma 2018 | withdrawn | Phase 1 | — |
| NCT06287229 | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab 2024 | recruiting | PHASE1, PHASE2 | 40 |
| NCT07422337 | A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab 2026 | recruiting | Not applicable | 300 |
Published literature
- Clinical trial publication A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisTuscano JM, Othman T, Frankel P et al. · Blood advances · 2026 · PMID 41213001
- Clinical trial publication Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomabNägele V, Zugmaier G, Goebeler ME et al. · Experimental hematology · 2021 · PMID 34228983
- Clinical trial publication Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphomaCoyle L, Morley NJ, Rambaldi A et al. · Leukemia & lymphoma · 2020 · PMID 32546071
- Clinical trial publication Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin LymphomaHijazi Y, Klinger M, Kratzer A et al. · Current clinical pharmacology · 2018 · PMID 29773068
- Clinical trial publication Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyGoebeler ME, Knop S, Viardot A et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · PMID 26884582
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Blinatumomab approved for Non-Hodgkin Lymphoma (NHL)?
Blinatumomab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Blinatumomab in clinical trials for Non-Hodgkin Lymphoma (NHL)?
ClinicalTrials.gov lists 8 registered trials linking Blinatumomab to Non-Hodgkin Lymphoma (NHL): 5 are currently recruiting; 2 are active or not yet recruiting; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT07476729). It plans or enrolled 750 participants. Registration activity spans 2017 to 2026.
What does the evidence show for Blinatumomab in Non-Hodgkin Lymphoma (NHL)?
Trials of Blinatumomab in Non-Hodgkin Lymphoma (NHL) are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.